Literature DB >> 3567968

Multivesicular liposomes containing cytarabine for slow-release Sc administration.

S Kim, S B Howell.   

Abstract

Sc administration of cytarabine entrapped in multivesicular liposomes to BDF1 mice resulted in slow first-order release from skin, with a half-life of 4 days. The half-life was 10 minutes for unencapsulated free drug. A single-dose sc treatment of BDF1 mice, inoculated iv with 10(5) L1210 leukemia cells 24 hours previously, resulted in long-term survivors over a wide dose range. This study demonstrates that encapsulation of cytarabine in multivesicular liposomes results in slow release from skin and that a single sc dose is often curative for mice with systemic leukemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567968

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.

Authors:  Martin S Angst; David R Drover
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Multivesicular liposomes containing bleomycin for subcutaneous administration.

Authors:  R Roy; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

4.  Extended-release formulation of morphine for subcutaneous administration.

Authors:  T Kim; J Kim; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.

Authors:  Irene B Vazquez Fuster; Amanda R Taylor; Annette N Smith; Sue H Duran; William R Ravis; Shanese L Jasper; Robert D Arnold
Journal:  J Vet Intern Med       Date:  2020-05-22       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.